Drug Profile
AMG 172
Alternative Names: AMG172Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Amgen
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Renal cell carcinoma
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 05 Dec 2012 Phase-I clinical trials in Renal cell carcinoma (second-line therapy or greater) in France (Parenteral) (NCT01497821)
- 05 Dec 2012 Phase-I clinical trials in Renal cell carcinoma (second-line therapy or greater) in Germany (Parenteral) (NCT01497821)